Siloam Biosciences, Inc., founded in 2004, is focused on developing the next generation of diagnostic systems using innovative microfluidics for immunoassay based diagnostics. Siloam Biosciences, Inc., has developed the first ever open source Point-of-Care Test platform. The TROVA™ POCT platform allows for ultra-high sensitivity and wide dynamic range assays to be developed within a very short time. To-date the TROVA™ POCT platform has been tested to demonstrate:
- Ultra-high sensitivity cardiac Troponin-I assay with sensitivity of ~ 20 pg/mL
- Wide dynamic range HCG assay with 4-Log operating range
The TROVA™ platform is driven by Siloam’s market-proven Optimiser™ technology platform that integrates the power of microfluidics in an easy-to-use platform. This allows for a unique competitive advantage to companies adopting the TROVA™ platform – any new ELISA test can be adapted to a POCT format within ~3-4 months. Over 70 assays have been developed on the underlying Optimiser™ technology platform proving the robustness and universal nature of this platform.
Siloam invites diagnostic development companies to learn how our TROVA™ POCT system powered by Optimiser™ technology can develop the next-gen POCT system. Please visit the Strategic Partners page for additional details.
Our proven Optimiser™ microfluidic platform is also commercially offered to the life science research market offering users unheard of enhancements in automation workflow and improved assay throughput with 13 minute sandwich ELISAs using sample sizes less than 2 ul. Optimiser™ technology also allows users to tune their assays for enhanced sensitivity yielding up to 1000-fold higher sensitivity than conventional ELISA and to provides a much broader dynamic range with no change in reagents.